Qualigen Therapeutics Inc (QLGN) — Cash Flow-to-Debt Ratio
Qualigen Therapeutics Inc (QLGN) has a Cash Flow-to-Debt Ratio of -0.43x as of September 2025, meaning its operating cash flow of $-2.14 Million could theoretically repay 0% of its total liabilities ($4.92 Million) in one year. See financial agility of Qualigen Therapeutics Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Qualigen Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Qualigen Therapeutics Inc across 13 annual periods. For the full cash flow conversion analysis, see Qualigen Therapeutics Inc (QLGN) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Qualigen Therapeutics Inc (2012–2024)
Year-by-year debt coverage analysis for Qualigen Therapeutics Inc. Check Qualigen Therapeutics Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -3.15x | $-6.33 Million | $2.01 Million | ▼ -26.5% |
| 2023 | -2.49x | $-10.30 Million | $4.14 Million | ▼ -94.0% |
| 2022 | -1.28x | $-13.25 Million | $10.32 Million | ▲ +45.3% |
| 2021 | -2.35x | $-14.73 Million | $6.27 Million | ▼ -160.8% |
| 2020 | -0.90x | $-9.76 Million | $10.83 Million | ▼ -2765.8% |
| 2019 | 0.03x | $57.33K | $1.70 Million | ▲ +101.5% |
| 2018 | -2.25x | $-13.33 Million | $5.93 Million | ▲ +17.8% |
| 2017 | -2.73x | $-7.40 Million | $2.71 Million | ▲ +43.7% |
| 2016 | -4.85x | $-15.21 Million | $3.13 Million | ▼ -14.9% |
| 2015 | -4.22x | $-5.72 Million | $1.35 Million | ▼ -357.9% |
| 2014 | -0.92x | $-1.16 Million | $1.25 Million | ▲ +57.7% |
| 2013 | -2.18x | $-1.96 Million | $897.96K | ▲ +35.5% |
| 2012 | -3.38x | $-3.08 Million | $910.48K | — |